Advances in multiple myeloma: key updates from the ASH 2025 meeting
- Study type
- Review article
- Study name
- ASH 2025 MM
- Design
- Review editorial on multiple myeloma abstracts at the ASH 2025 meeting (not a primary clinical study)
- Sample size
- Not stated in the abstract
- Source
- J Hematol Oncol · 2026
In plain words
This paper summarises the most important new findings on treating multiple myeloma presented at a major blood disorders congress. New immune treatments, especially bispecific antibodies, have shown promising results at different stages of the disease, and in one study a combination including teclistamab improved survival in patients whose disease had come back. These treatments can cause infections and low blood counts, so close monitoring is needed. The choice of treatment should be made only with your treating doctor's advice.
Key results
Study population
This editorial reviews patients with multiple myeloma at all stages of the disease: newly diagnosed multiple myeloma (NDMM), transplant-ineligible (TIE) NDMM, early relapsed/refractory myeloma (RRMM) and extramedullary myeloma (EMM). The inclusion criteria of each study are not given in the abstract.
Endpoints
As a review editorial, it has no primary endpoint. Endpoints reported from the reviewed studies include conversion from MRD-positive to MRD-negative, depth of response, progression-free survival (PFS), overall survival (OS), response rate, safety and infection risk.
Safety and side effects
According to the abstract: in the MagnetisMM-30 study, cytopenias were reported with the combination of elranatamab and iberdomide. In the TecLille study, the infection risk with antibody-only treatment was described as "manageable". The authors stress the importance of infection risk mitigation and long-term safety assessment. Rates of grade ≥3 adverse events are not given in the abstract.
Clinical significance and place in guidelines
According to the abstract, findings presented at ASH 2025 show bispecific antibody immunotherapy moving into earlier stages of the disease, and MRD-adapted approaches may guide treatment intensification. The importance of infection mitigation and long-term safety follow-up is also highlighted. This editorial is not itself a clinical guideline, and the abstract says nothing about drug approvals or guideline adoption. Regulatory status and clinical guidelines should be checked separately.
Limitations
This text is an editorial summarising meeting abstracts and is not a primary trial. Some of the data reviewed may be preliminary or reported only in conference abstracts. The abstract does not give exact figures (sample size, hazard ratios, response rates or adverse event rates). For clinical judgement, the full text and the primary publications of each study should be consulted.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.